Yoshimoto A, Matsuzawa Y, Oki T, Takeuchi T, Umezawa H
J Antibiot (Tokyo). 1981 Aug;34(8):951-8. doi: 10.7164/antibiotics.34.951.
During genetic study on obtaining high-yield variants of aclacinomycin A-producer, a variety of blocked mutants were isolated from Streptomyces galilaeus MA144-M1 and were characterized. The isolated mutants included those which accumulated only specific components of parental glycosides, those which produced new aklavinone glycosides devoid of parental rhodosamine or both rhodinose and cinerulose, those which produced non-glycosidic aglycones, and antibiotic-negative mutants, some of which were able to glycosidate exogenous aklavinone. By biotransformation with the aglycone feeding culture, the precursor activity of new aglycones was also tested. From the results and in relation to the characterization of isolated mutants, the biosynthetic pathway of aclacinomycin A and related antibiotics is discussed.
在对阿克拉霉素A产生菌的高产变体进行遗传学研究过程中,从加利利链霉菌MA144-M1中分离出多种阻断突变体并对其进行了表征。分离出的突变体包括仅积累亲本糖苷特定成分的突变体、产生不含亲本罗糖胺或鼠李糖和灰黄糖的新阿克拉维酮糖苷的突变体、产生非糖苷配基的突变体以及抗生素阴性突变体,其中一些能够对外源阿克拉维酮进行糖基化。通过糖苷配基补料培养进行生物转化,还测试了新糖苷配基的前体活性。根据这些结果并结合分离突变体的表征,对阿克拉霉素A及相关抗生素的生物合成途径进行了讨论。